在第4周,GLPG3667高剂量组10名患者中有4名达到PASI50应答(银屑病面积与严重指数[PASI]较基线改善至少50%)反应,安慰剂组10名患者中有1名达到PASI50应答。而GLPG3667低剂量组没有患者达到PASI50应答。GLPG3667高剂量组4名应答患者的PASI评分分别较基线水平改善了52%、65%、74%、81%,而安慰剂组的1名应...
GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseasesand is in Phase 2for dermatomyositis Mechelen, Belgium; 28 August 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announc...
[关键字]:GLPG3667 TYK2抑制剂 银屑病 健康网讯: